Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 411 to 420 of 2450 total matches.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
months), and an optimal sequence of treatment has
not been established.1,2
Some patients with advanced ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
Thoracic Society and the Infectious Diseases Society
of America (ATS/IDSA) were updated in 2019.1 ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
FDA Authorizes Moderna COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
on December 11, 2020.1
CLINICAL STUDY — Issuance of the EUA was based
primarily on the results ...
On December 18, 2020, the FDA issued an Emergency
Use Authorization (EUA) for the Moderna mRNA-based
vaccine for prevention of COVID-19 in persons
≥18 years old. The Pfizer-BioNTech mRNA-based
vaccine received an FDA EUA for the same indication
in persons ≥16 years old on December 11, 2020.
Encorafenib (Braftovi) for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
,
and oxaliplatin).1 After failure of initial therapy,
subsequent lines of therapy have minimal efficacy ...
The FDA has approved the oral kinase inhibitor
encorafenib (Braftovi – Pfizer), in combination with
the epidermal growth factor receptor (EGFR) inhibitor
cetuximab (Erbitux), for treatment of adults with
metastatic colorectal cancer (CRC) with a BRAF
V600E mutation. Encorafenib was approved in 2018
for use with the mitogen-activated kinase (MEK)
inhibitor binimetinib (Mektovi) for treatment of
unresectable or metastatic melanoma with a BRAF
V600E or V600K mutation.
In Brief: Semglee - A New Insulin Glargine for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
), an insulin
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults ...
The FDA has approved Semglee (Mylan), an insulin
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults and type 2
diabetes in adults. Semglee is the second "follow-on"
insulin glargine product to become available in
the US; Basaglar, which is also similar to Lantus, was
the first. Lantus is a recombinant analog of human
insulin that forms microprecipitates in subcutaneous
tissue, prolonging its duration of action to a mean of
about 24 hours with no pronounced peak effect.
In Brief: An Asenapine Patch (Secuado) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
1). Asenapine was also superior to placebo in
the Clinical Global Impressions-Severity (CGI ...
A transdermal formulation of the second-generation
(atypical) antipsychotic asenapine (Secuado – Noven)
has been approved by the FDA for once-daily treatment of
schizophrenia in adults. Asenapine is the first antipsychotic
to become available in a transdermal formulation in the US.
A twice-daily sublingual tablet formulation of asenapine
(Saphris) has been available since 2009.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
43,548 subjects ≥16 years old were randomized 1:1
to receive 30 mcg of the Pfizer-BioNTech vaccine ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
uncomplicated influenza in patients
≥12 years old in 2018.1 Two neuraminidase inhibitors
are FDA-approved ...
The oral polymerase acidic endonuclease inhibitor
baloxavir marboxil (Xofluza — Genentech) is now FDAapproved
for post-exposure prophylaxis of influenza
in patients ≥12 years old. Baloxavir was approved for
treatment of acute uncomplicated influenza in patients
≥12 years old in 2018.1 Two neuraminidase inhibitors
are FDA-approved for prophylaxis of influenza:
oseltamivir (Tamiflu, and generics) in patients ≥1 year
old, and zanamivir (Relenza) in patients ≥5 years old.2
Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved
for pre-exposure prophylaxis of...
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
clinical trials, opicapone significantly reduced “off” time by
about 1 hour, compared to placebo. In one ...
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
prolongation and cardiac
arrythmias.1,2 The macrolide antibiotics erythromycin
and azithromycin ...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.